https://policybase.cma.ca/link/policy14443

POLICY TYPE
Policy endorsement

DATE
2021-06-24

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Taking action on drug shortages during Covid-19 - open letter

https://policybase.cma.ca/link/policy14261

POLICY TYPE  Parliamentary submission
DATE  2020-08-13
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents

[Image of a letter with a backdrop of the Canadian Medical Association logo]

Dear [Name],

I am writing to share important information about drug shortages during Covid-19. These shortages have been widespread and can be attributed to various factors.

As the pandemic continues, shortages of certain medications have been reported across the country. The Canadian Medical Association (CMA) has been advocating for action to address these shortages.

The CMA has called for the government to take immediate action to ensure a sufficient supply of essential medications. This includes increasing the production of key medications and providing financial support to companies that manufacture essential drugs.

I believe it is crucial for the government to address these shortages to ensure the health and well-being of all Canadians. Please consider supporting these efforts and taking action to prevent future shortages.

Sincerely,

[Your Name]
Authorizing Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy11514

POLICY TYPE
Policy document

LAST REVIEWED
2020-02-29

DATE
2015-02-28

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on reducing youth access and appeal of vaping products
https://policybase.cma.ca/link/policy14078

POLICY TYPE  Response to consultation
DATE  2019-05-24
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
 Population health, health equity, public health

Documents
Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy10045

POLICY TYPE
Policy document

LAST REVIEWED
2019-03-03

DATE
2010-12-04

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA POLICY

Cannabis for Medical Purposes

1. Increase support for the advancement of scientific knowledge about the medical use of cannabis.
2. Support the development of guidelines for the medical use of cannabis.
3. Support the development of guidelines for the medical use of cannabis.
4. Support the development of guidelines for the medical use of cannabis.
5. Support the development of guidelines for the medical use of cannabis.
6. Support the development of guidelines for the medical use of cannabis.

The Council on Medical Ethics (CME) has prepared the following guidelines for the use of cannabis for medical purposes:

1. Increase support for the advancement of scientific knowledge about the medical use of cannabis.
2. Support the development of guidelines for the medical use of cannabis.
3. Support the development of guidelines for the medical use of cannabis.
4. Support the development of guidelines for the medical use of cannabis.
5. Support the development of guidelines for the medical use of cannabis.
6. Support the development of guidelines for the medical use of cannabis.

The Council on Medical Ethics (CME) has prepared the following guidelines for the use of cannabis for medical purposes:

1. Increase support for the advancement of scientific knowledge about the medical use of cannabis.
2. Support the development of guidelines for the medical use of cannabis.
3. Support the development of guidelines for the medical use of cannabis.
4. Support the development of guidelines for the medical use of cannabis.
5. Support the development of guidelines for the medical use of cannabis.
6. Support the development of guidelines for the medical use of cannabis.
MEDICATION USE AND SENIORS

6/UPDATE 2017

The Canadian Medical Association recommends that every effort be made to improve the quality of care for frail elderly people. This includes minimizing medication use, ensuring that the patient understands the benefits and risks of medication, and ensuring that the patient’s goals of care are respected.

The use of multiple medications increases the risk of adverse drug events and the risk of drug interactions. The risk of adverse drug events is higher in the elderly population. The use of multiple medications may also result in drug toxicity, which can lead to hospitalization and increased healthcare costs.

The Canadian Medical Association recommends that physicians and pharmacists work together to develop a comprehensive medication review for each patient. This review should include an assessment of the patient’s medication history, current medications, and any previous medication-related problems. The review should also consider the patient’s goals of care and the potential for medication-related adverse events.

The Canadian Medical Association recommends that physicians and pharmacists work together to develop a comprehensive medication review for each patient. This review should include an assessment of the patient’s medication history, current medications, and any previous medication-related problems. The review should also consider the patient’s goals of care and the potential for medication-related adverse events.
Vision for e-Prescribing: a joint statement by the Canadian Medical Association and the Canadian Pharmacists Association

https://policybase.cma.ca/link/policy10670

POLICY TYPE  Policy document
LAST REVIEWED  2019-03-03
DATE  2012-12-08
TOPICS  Health information and e-health
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on edible cannabis, extracts & topicals
https://policybase.cma.ca/link/policy14020

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Response to consultation</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2019-02-20</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Pharmaceuticals, prescribing, cannabis, drugs</td>
</tr>
<tr>
<td></td>
<td>Population health, health equity, public health</td>
</tr>
</tbody>
</table>

Documents
Health Canada consultation on Canadian drugs and substances strategy
https://policybase.cma.ca/link/policy14017

POLICY TYPE  Response to consultation
DATE  2018-12-04
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Implementation of National Pharmacare
https://policybase.cma.ca/link/policy13933

POLICY TYPE
Response to consultation

DATE
2018-10-02

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on tobacco products regulations (plain and standardized appearance)
https://policybase.cma.ca/link/policy13930

POLICY TYPE: Response to consultation
DATE: 2018-09-06
TOPICS: Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Support life-saving supervised consumption and overdose prevention sites:
open letter to Premier Doug Ford and Health Minister Christine Elliott
https://policybase.cma.ca/link/policy13931

POLICY TYPE
Policy endorsement

DATE
2018-08-30

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on regulatory amendments regarding tramadol
https://policybase.cma.ca/link/policy13927

POLICY TYPE
Response to consultation

DATE
2018-08-14

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on restriction of marketing and advertising of opioids
https://policybase.cma.ca/link/policy13921

POLICY TYPE: Response to consultation
DATE: 2018-07-18
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on proposed front-of-package labelling
https://policybase.cma.ca/link/policy13882

POLICY TYPE  Response to consultation
DATE  2018-04-23
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

Dear [HCP Name],

The Canadian Medical Association (CMA) welcomes the opportunity to provide comments on the各省(市)地方标准备案管理办法 ( QB 41/T 0010-2021) and its impact on public health. The CMA is the national medical association representing more than 60,000 physicians and supporting them in advancing individual and population health.

The CMA believes that public health is a shared responsibility, involving all sectors of government, the health care system, and individuals. Effective policies and actions can help improve health outcomes and reduce health inequities.

Front-of-Package Labelling

The CMA has expressed its commitment to a balanced approach to FOP labelling, which considers both public health and consumer needs. The CMA supports evidence-based policies that encourage healthy choices and provide accurate information to consumers.

In this context, the CMA welcomes the opportunity to provide input on the proposed front-of-package labelling standards. We applaud the efforts of provincial and territorial governments to develop comprehensive strategies that promote public health and patient safety.

The CMA recommends the following considerations when developing front-of-package labelling standards:

1. **Balance**: Ensure that labelling policies are balanced, providing clear and accessible information without creating confusion.
2. **Scientific Evidence**: Base labelling requirements on robust scientific evidence that supports public health goals.
3. **Cultural Sensitivity**: Be mindful of cultural and regional differences in how health information is understood and acted upon.
4. **Consumer Engagement**: Involve consumers and stakeholders in the development and implementation of labelling policies to ensure they are relevant and effective.

We look forward to continuing our dialogue with policymakers and stakeholders to ensure that front-of-package labelling policies are effective, equitable, and aligned with public health goals.

Sincerely,

[Your Name]
Canadian Medical Association

[Date]
Bill C-45: The Cannabis Act

https://policybase.cma.ca/link/policy13861

POLICY TYPE  Parliamentary submission
DATE  2018-04-18
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA's Recommendations for Bill S-5 An Act to amend the Tobacco Act and
the Non-smokers’ Health Act and to make consequential amendments to
other Acts

https://policybase.cma.ca/link/policy13918

POLICY TYPE
Parliamentary submission

DATE
2018-02-15

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents
Proposed approach to the regulation of cannabis

https://policybase.cma.ca/link/policy13838

POLICY TYPE  Response to consultation
DATE  2018-01-19
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Excise duty framework for cannabis products
https://policybase.cma.ca/link/policy13799

POLICY TYPE                   Response to consultation
DATE                      2017-12-07
TOPICS                    Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission:
Excise Duty Framework for Cannabis Products

Submission to the Government of Canada consultation on
the proposed excise duty framework for cannabis products

December 7, 2017
Non-prescription availability of low-dose codeine products
https://policybase.cma.ca/link/policy13734

POLICY TYPE
Response to consultation

DATE
2017-11-7

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission:
Non-Prescription Availability of Low-Dose Codeine Products

Submission to the Health Canada consultation on the potential risks, benefits and impacts of changes to the regulations to the Controlled Drugs and Substances Act that would require all products containing codeine to be sold by prescriber only.

November 7, 2017